These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 26712693)

  • 1. Silencing of CD24 Enhances the PRIMA-1-Induced Restoration of Mutant p53 in Prostate Cancer Cells.
    Zhang W; Yi B; Wang C; Chen D; Bae S; Wei S; Guo RJ; Lu C; Nguyen LL; Yang WH; Lillard JW; Zhang X; Wang L; Liu R
    Clin Cancer Res; 2016 May; 22(10):2545-54. PubMed ID: 26712693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A CD24-p53 axis contributes to African American prostate cancer disparities.
    Liu W; Zhang Y; Wei S; Bae S; Yang WH; Smith GJ; Mohler JL; Fontham ETH; Bensen JT; Sonpavde GP; Chen GY; Liu R; Wang L
    Prostate; 2020 May; 80(8):609-618. PubMed ID: 32168400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 mutant-type in human prostate cancer cells determines the sensitivity to phenethyl isothiocyanate induced growth inhibition.
    Aggarwal M; Saxena R; Asif N; Sinclair E; Tan J; Cruz I; Berry D; Kallakury B; Pham Q; Wang TTY; Chung FL
    J Exp Clin Cancer Res; 2019 Jul; 38(1):307. PubMed ID: 31307507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracellular CD24 disrupts the ARF-NPM interaction and enables mutational and viral oncogene-mediated p53 inactivation.
    Wang L; Liu R; Ye P; Wong C; Chen GY; Zhou P; Sakabe K; Zheng X; Wu W; Zhang P; Jiang T; Bassetti MF; Jube S; Sun Y; Zhang Y; Zheng P; Liu Y
    Nat Commun; 2015 Jan; 6():5909. PubMed ID: 25600590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ID4 regulates transcriptional activity of wild type and mutant p53 via K373 acetylation.
    Morton DJ; Patel D; Joshi J; Hunt A; Knowell AE; Chaudhary J
    Oncotarget; 2017 Jan; 8(2):2536-2549. PubMed ID: 27911860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant TP53 G245C and R273H promote cellular malignancy in esophageal squamous cell carcinoma.
    Kang N; Wang Y; Guo S; Ou Y; Wang G; Chen J; Li D; Zhan Q
    BMC Cell Biol; 2018 Aug; 19(1):16. PubMed ID: 30126368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of
    Guedes LB; Almutairi F; Haffner MC; Rajoria G; Liu Z; Klimek S; Zoino R; Yousefi K; Sharma R; De Marzo AM; Netto GJ; Isaacs WB; Ross AE; Schaeffer EM; Lotan TL
    Clin Cancer Res; 2017 Aug; 23(16):4693-4703. PubMed ID: 28446506
    [No Abstract]   [Full Text] [Related]  

  • 8. The DU145 human prostate carcinoma cell line harbors a temperature-sensitive allele of p53.
    Bajgelman MC; Strauss BE
    Prostate; 2006 Sep; 66(13):1455-62. PubMed ID: 16741917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA interference targeting mutant p53 inhibits growth and induces apoptosis in DU145 human prostate cancer cells.
    Zhu H; Mao Q; Lin Y; Yang K; Xie L
    Med Oncol; 2011 Dec; 28 Suppl 1():S381-7. PubMed ID: 20857345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD24 is a genetic modifier for risk and progression of prostate cancer.
    Zhang Y; Li B; Zhang X; Sonpavde GP; Jiao K; Zhang A; Zhang G; Sun M; Chu C; Li F; Wang L; Cui R; Liu R
    Mol Carcinog; 2017 Feb; 56(2):641-650. PubMed ID: 27377469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of p53 gene polymorphism on functions of prostate cancer cells.
    Chi N; Yun ZZ; Tan ZH; Li XZ; Chen BT; Liu J; Xu LB; Ma KW; Li SX; Liu JF; Liu CX
    Genet Mol Res; 2015 Oct; 14(4):11700-9. PubMed ID: 26436494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PRIMA-1, a mutant p53 reactivator, restores the sensitivity of TP53 mutant-type thyroid cancer cells to the histone methylation inhibitor 3-Deazaneplanocin A.
    Cui B; Yang Q; Guan H; Shi B; Hou P; Ji M
    J Clin Endocrinol Metab; 2014 Jun; 99(6):E962-70. PubMed ID: 24512488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PRIMA-1 synergizes olaparib-induced cell death in p53 mutant triple negative human breast cancer cell line via restoring p53 function, arresting cell cycle, and inducing apoptosis.
    Zaza M; Rashed MH; Elrefaey H; Hassan MH; Abo-Salem OM; El-Sayed ESM
    Can J Physiol Pharmacol; 2024 Jan; 102(1):55-68. PubMed ID: 37818839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Id4 dependent acetylation restores mutant-p53 transcriptional activity.
    Knowell AE; Patel D; Morton DJ; Sharma P; Glymph S; Chaudhary J
    Mol Cancer; 2013 Dec; 12():161. PubMed ID: 24330748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.
    Hosain SB; Khiste SK; Uddin MB; Vorubindi V; Ingram C; Zhang S; Hill RA; Gu X; Liu YY
    Oncotarget; 2016 Sep; 7(37):60575-60592. PubMed ID: 27517620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis.
    Lambert JM; Moshfegh A; Hainaut P; Wiman KG; Bykov VJ
    Oncogene; 2010 Mar; 29(9):1329-38. PubMed ID: 19946333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant Kras-induced upregulation of CD24 enhances prostate cancer stemness and bone metastasis.
    Weng CC; Ding PY; Liu YH; Hawse JR; Subramaniam M; Wu CC; Lin YC; Chen CY; Hung WC; Cheng KH
    Oncogene; 2019 Mar; 38(12):2005-2019. PubMed ID: 30467381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF).
    Tan BS; Tiong KH; Choo HL; Chung FF; Hii LW; Tan SH; Yap IK; Pani S; Khor NT; Wong SF; Rosli R; Cheong SK; Leong CO
    Cell Death Dis; 2015 Jul; 6(7):e1826. PubMed ID: 26181206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Murine double minute 2 siRNA and wild-type p53 gene therapy interact positively with zinc on prostate tumours in vitro and in vivo.
    Gu J; Wang B; Liu Y; Zhong L; Tang Y; Guo H; Jiang T; Wang L; Li Y; Cai L
    Eur J Cancer; 2014 Apr; 50(6):1184-94. PubMed ID: 24447832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant p53 and mTOR/PKM2 regulation in cancer cells.
    Dando I; Cordani M; Donadelli M
    IUBMB Life; 2016 Sep; 68(9):722-6. PubMed ID: 27385486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.